Last reviewed · How we verify
F0434
F0434 is an investigational immunotherapy agent designed to modulate immune responses, likely through checkpoint inhibition or T-cell activation pathways.
At a glance
| Generic name | F0434 |
|---|---|
| Also known as | Gabapentin with thiamine and cobalamin |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details for F0434 are limited in public literature, Merck KGaA's phase 3 pipeline typically includes agents targeting immune checkpoints or enhancing anti-tumor immunity. The exact molecular target and mechanism require access to clinical trial protocols or company disclosures.
Approved indications
Common side effects
Key clinical trials
- Neuropathic Pain Management (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |